The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III, randomized, open-label study of triweekly docetaxel versus biweekly docetaxel as treatments for advanced hormone-refractory prostate cancer: Findings from an interim safety analysis of the Finnish Uro-oncological Group Study 1-2003.
Petteri Hervonen
No relevant relationships to disclose
Heikki Joensuu
No relevant relationships to disclose
Timo K. Joensuu
No relevant relationships to disclose
Paul Nyandoto
No relevant relationships to disclose
Marjaana Luukkaa
No relevant relationships to disclose
Sten Nilsson
No relevant relationships to disclose
Akseli E. Hemminki
No relevant relationships to disclose
Raija Asola
No relevant relationships to disclose
Tiina Luukkaala
No relevant relationships to disclose
Pirkko-Liisa Kellokumpu-Lehtinen
No relevant relationships to disclose